Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 57

1.

The utility of patient reported data in a gynecologic oncology clinic.

Barnes D, Rivera R, Gibson S, Craig C, Cragun J, Monk B, Chase D.

Gynecol Oncol Res Pract. 2018 Jul 12;5:4. doi: 10.1186/s40661-018-0062-4. eCollection 2018.

2.

Socio-demographic characteristics influencing cervical cancer screening intention of HIV-positive women in the central region of Ghana.

Ebu NI.

Gynecol Oncol Res Pract. 2018 Mar 7;5:3. doi: 10.1186/s40661-018-0060-6. eCollection 2018.

3.

Improving attendance to genetic counselling services for gynaecological oncology patients.

Pokharel HP, Hacker NF, Andrews L.

Gynecol Oncol Res Pract. 2018 Jan 10;5:2. doi: 10.1186/s40661-018-0059-z. eCollection 2018.

4.

Clinical trial experience with CA4P anticancer therapy: focus on efficacy, cardiovascular adverse events, and hypertension management.

Grisham R, Ky B, Tewari KS, Chaplin DJ, Walker J.

Gynecol Oncol Res Pract. 2018 Jan 5;5:1. doi: 10.1186/s40661-017-0058-5. eCollection 2018. Review.

5.

Comprehensive knowledge and uptake of cervical cancer screening is low among women living with HIV/AIDS in Northwest Ethiopia.

Erku DA, Netere AK, Mersha AG, Abebe SA, Mekuria AB, Belachew SA.

Gynecol Oncol Res Pract. 2017 Dec 19;4:20. doi: 10.1186/s40661-017-0057-6. eCollection 2017.

6.

New therapies for advanced, recurrent, and metastatic endometrial cancers.

Makker V, Green AK, Wenham RM, Mutch D, Davidson B, Miller DS.

Gynecol Oncol Res Pract. 2017 Dec 2;4:19. doi: 10.1186/s40661-017-0056-7. eCollection 2017. Review.

7.

PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers.

Sisay M, Edessa D.

Gynecol Oncol Res Pract. 2017 Nov 29;4:18. doi: 10.1186/s40661-017-0055-8. eCollection 2017. Review.

8.

A retrospective evaluation of activity of gemcitabine/platinum regimens in the treatment of recurrent ovarian cancer.

Le TN, Harvey RE, Kim CK, Brown J, Coleman RL, Smith JA.

Gynecol Oncol Res Pract. 2017 Nov 14;4:16. doi: 10.1186/s40661-017-0053-x. eCollection 2017.

9.

EZH2 inhibition in ARID1A mutated clear cell and endometrioid ovarian and endometrioid endometrial cancers.

Alldredge JK, Eskander RN.

Gynecol Oncol Res Pract. 2017 Oct 31;4:17. doi: 10.1186/s40661-017-0052-y. eCollection 2017. Review.

10.

Assessment of drug therapy problems among patients with cervical cancer at Kenyatta National Hospital, Kenya.

Degu A, Njogu P, Weru I, Karimi P.

Gynecol Oncol Res Pract. 2017 Oct 18;4:15. doi: 10.1186/s40661-017-0054-9. eCollection 2017.

11.

Preparation in the business and practice of medicine: perspectives from recent gynecologic oncology graduates and program directors.

Schlumbrecht M, Siemon J, Morales G, Huang M, Slomovitz B.

Gynecol Oncol Res Pract. 2017 Sep 22;4:14. doi: 10.1186/s40661-017-0051-z. eCollection 2017.

12.

Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need?

Herzog TJ, Monk BJ.

Gynecol Oncol Res Pract. 2017 Sep 7;4:13. doi: 10.1186/s40661-017-0050-0. eCollection 2017. Review.

13.
14.

Multidisciplinary approach to manage antenatally suspected placenta percreta: updated algorithm and patient outcomes.

Lee PS, Kempner S, Miller M, Dominguez J, Grotegut C, Ehrisman J, Previs R, Havrilesky LJ, Broadwater G, Ellestad SC, Secord AA.

Gynecol Oncol Res Pract. 2017 Aug 22;4:11. doi: 10.1186/s40661-017-0049-6. eCollection 2017.

15.

Therapeutic options for treatment of human papillomavirus-associated cancers - novel immunologic vaccines: ADXS11-001.

Miles B, Safran HP, Monk BJ.

Gynecol Oncol Res Pract. 2017 Jul 14;4:10. doi: 10.1186/s40661-017-0047-8. eCollection 2017. Review.

16.

Fifth annual workshop of cytoreductive surgery for advanced ovarian cancer and peritoneal surface malignancies.

Tewari KS.

Gynecol Oncol Res Pract. 2016 Oct 24;3:10. doi: 10.1186/s40661-016-0031-8. eCollection 2016.

17.

Mechanistic insights into ADXS11-001 human papillomavirus-associated cancer immunotherapy.

Miles BA, Monk BJ, Safran HP.

Gynecol Oncol Res Pract. 2017 Jun 2;4:9. doi: 10.1186/s40661-017-0046-9. eCollection 2017. Review.

18.

Erratum to: Options in human papillomavirus (HPV) detection for cervical cancer screening: comparison between full genotyping and a rapid qualitative HPV-DNA assay in Ghana.

Obiri-Yeboah D, Adu-Sarkodie Y, Djigma F, Akakpo K, Aniakwa-Bonsu E, Amoako-Sakyi D, Simpore J, Mayaud P.

Gynecol Oncol Res Pract. 2017 Mar 23;4:8. doi: 10.1186/s40661-017-0044-y. eCollection 2017.

19.

Will bevacizumab biosimilars impact the value of systemic therapy in gynecologic cancers?

Monk BJ, Huh WK, Rosenberg JA, Jacobs I.

Gynecol Oncol Res Pract. 2017 Mar 21;4:7. doi: 10.1186/s40661-017-0045-x. eCollection 2017. Review.

20.

Preference of elderly patients' to oral or intravenous chemotherapy in heavily pre-treated recurrent ovarian cancer: final results of a prospective multicenter trial.

Chekerov R, Harter P, Fuxius S, Hanker LC, Woelber L, Müller L, Klare P, Abenhardt W, Nedkova Y, Yalcinkaya I, Heinrich G, Sommer H, Mahner S, Wimberger P, Koensgen-Mustea D, Richter R, Oskay-Oezcelik G, Sehouli J; Ovarian Cancer Study Group of the North-Eastern German Society of Gynaecological Oncology (NOGGO).

Gynecol Oncol Res Pract. 2017 Mar 7;4:6. doi: 10.1186/s40661-017-0040-2. eCollection 2017.

Supplemental Content

Loading ...
Support Center